Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist of the ghrelin receptor (growth hormone secretagogue receptor, GHSR-1a). It was developed as a growth hormone-releasing peptide (GHRP) with improved receptor selectivity compared to earlier compounds in its class. Ipamorelin is widely studied in preclinical research for its ability to stimulate growth hormone (GH) secretion from pituitary somatotrophs in a dose-dependent manner.

A key area of research interest surrounding Ipamorelin is its high selectivity for GH release with minimal concurrent effects on cortisol, prolactin, or ACTH — hormones commonly stimulated by less selective GHRPs. Studies in animal models have characterized its pharmacokinetic profile, receptor binding affinity, and GH pulse amplitude effects. Ipamorelin is frequently investigated in combination with GHRH analogs such as CJC-1295 to examine the additive or synergistic effects of simultaneous GHRH receptor and GHSR activation on total GH secretion.

Ipamorelin is a standard research compound in growth hormone axis studies, metabolic research, and peptide pharmacology. Its well-characterized receptor selectivity and consistent GH-stimulating effects in animal models make it a reliable tool for researchers examining pituitary function and growth hormone secretagogue mechanisms.

Disclaimer: This product is intended for in vitro research and laboratory use only. It is not intended for human or veterinary use, consumption, or injection. Not approved by the FDA. Not intended to diagnose, treat, cure, or prevent any disease or medical condition. For use by qualified researchers only.